Roth Capital set a $24.00 price target on Recro Pharma Inc. (NASDAQ:REPH) in a research report released on Monday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Brean Capital reissued a buy rating and set a $28.00 price objective on shares of Recro Pharma in a research report on Thursday, August 11th. Aegis started coverage on shares of Recro Pharma in a report on Monday, November 14th. They issued a buy rating and a $21.00 target price on the stock. HC Wainwright reaffirmed a buy rating on shares of Recro Pharma in a report on Monday, November 14th. Zacks Investment Research raised shares of Recro Pharma from a sell rating to a hold rating in a report on Friday, August 26th. Finally, Janney Montgomery Scott started coverage on shares of Recro Pharma in a report on Monday, August 29th. They issued a buy rating and a $21.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $19.13.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Shares of Recro Pharma (NASDAQ:REPH) opened at 8.00 on Monday. Recro Pharma has a 52 week low of $5.59 and a 52 week high of $12.50. The stock’s market cap is $97.30 million. The company’s 50-day moving average is $7.71 and its 200 day moving average is $8.33.

WARNING: “Roth Capital Analysts Give Recro Pharma Inc. (REPH) a $24.00 Price Target” was originally published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international copyright & trademark legislation. The correct version of this article can be accessed at http://www.financial-market-news.com/roth-capital-analysts-give-recro-pharma-inc-reph-a-24-00-price-target/1212130/.

Several hedge funds have recently made changes to their positions in REPH. Northern Trust Corp bought a new stake in shares of Recro Pharma during the third quarter valued at approximately $128,000. Granite Point Capital Management L.P. bought a new stake in shares of Recro Pharma during the third quarter valued at approximately $636,000. Wells Fargo & Company MN boosted its stake in shares of Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock valued at $276,000 after buying an additional 11,200 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Recro Pharma during the third quarter valued at approximately $140,000. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the period. Hedge funds and other institutional investors own 52.28% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.